Clinical Trial Update: Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a single-dose SP093 Typhoid Vi polysaccharide vaccine in Japanese subjects; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salmonellosis
• Typhoid Fever

Drugs mentioned

• SP093 Typhoid Vi Polysaccharide Vaccine (Vi polysaccharide vaccine (Typhi))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Salmonella Infections, Typhoid Fever | Phase 3 | Status: COMPLETED | Results posted: 2014-05-12